22.418 articles found

Immunotherapy for Parkinson's disease: a developing therapeutic strategy.

Bradbury J.

Drug Discov Today · 2005-08-01

DOI: 10.1016/s1359-6446(05)03562-2PMID: 16182188

Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.

Chan PL, Nutt JG, Holford NH.

J Pharmacokinet Pharmacodyn · 2005-08-01

DOI: 10.1007/s10928-005-0039-xPMID: 16320098

Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease.

Chan PL, Nutt JG, Holford NH.

J Pharmacokinet Pharmacodyn · 2005-08-01

DOI: 10.1007/s10928-005-0055-xPMID: 16320101

Treatment and Prevention of Th1 and 'Autoimmune' Diseases Effected with Antibiotics and/or Angiotensin Inhibition

MARSHALL TREVOR G.

· 2005-07-29

New heteroaryl derivatives are phosphodiesterase-4 enzyme inhibitors useful for the treatment of e.g. respiratory or gastrointestinal complaints or diseases, depression, Alzheimer's disease and Parkinson's disease

WALTER RAINER, ANDERSKEWITZ RALF, KLEY JOERG, DOLLINGER HORST, GOEGGEL ROLF, JUNG BIRGIT, MACK JUERGEN, NICKOLAUS PETER.

· 2005-07-29

Increase in plasma homocysteine levels induced by drug treatments in neurologic patients.

Siniscalchi A, Mancuso F, Gallelli L, Ferreri Ibbadu G, Biagio Mercuri N, De Sarro G.

Pharmacol Res · 2005-07-20

DOI: 10.1016/j.phrs.2005.05.013PMID: 16039138

Prevention and treatment of synucleinopathic and amyloidogenic disease

SCHENK DALE B, MASLIAH ELIEZER, BUTTINI MANUEL J, CHILCOTE TAMIE J, ROCKENSTEIN EDWARD M, GAMES KATE D.

· 2005-07-19

Description (reporting the actual words used in written letters) of the neuropsychological and psychopathological modifications produced by dopaminergic treatment in a young patient with Parkinson's disease.

Cannas A, Solla P, Floris G, Tacconi P, Fulgheri P, Congia S, Spissu A.

Prog Neuropsychopharmacol Biol Psychiatry · 2005-07-19

DOI: 10.1016/j.pnpbp.2005.06.015PMID: 16033704

SELECTIVE SEROTONIN 2A / 2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICES FOR NEURODEGENERATIVE DISEASES

WEINER DAVID M, DAVIS ROBERT E, BRANN MARK R.

· 2005-07-15

SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES.

MARK R BRANN.

· 2005-07-14

Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist

ROMANO STEVE.

· 2005-07-12

Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?

Lane EL, Cheetham SC, Jenner P.

Exp Neurol · 2005-07-11

DOI: 10.1016/j.expneurol.2005.06.006PMID: 16005456